SOPHiA GENETICS Earnings Call Signals Strong Momentum
SOPHiA GENETICS (SOPH) reported Q3 revenue of $24.3M, up 25% YoY, with record analysis volumes and improved adjusted EBITDA loss of $6.1M. U.S. revenue grew 41%, and new customer wins were highlighted. Challenges include FX pressure and implementation delays.
How this was made
The 30-second read
Why it matters
The earnings beat and loss narrowing provide a catalyst for short‑term price appreciation, while guidance on 2027 visibility supports a longer‑term bullish view.
Market read
First‑time disclosure of SOPH's Q3 financials and strategic wins offers a fresh data point for traders targeting AI‑driven health‑tech micro‑caps.
What to watch
FX pressure on euro/CHF revenues and front‑loaded bio‑pharma project costs may compress margins in the near term.
Background
SOPHiA Genetics (NASDAQ:SOPH) reported its Q3 2026 results, marking its strongest quarter to date with record analysis volumes and expanding U.S. customer base.
Ticker impact
Q3 earnings call disclosed 25% revenue growth to $24.3M, narrowed adjusted EBITDA loss and strong U.S. customer wins.
potential modest upside as investors price in higher revenue and narrowing losses
Revenue beat and loss compression are new primary data; market typically reacts positively to such earnings improvements for micro‑caps.
Market effects
Strengthens the genomics/AI‑driven diagnostics sector, highlighting demand for liquid‑biopsy and bio‑pharma collaborations.
U.S. market exposure benefits from 41% revenue growth, while European and APAC regions show double‑digit expansion.
Adds to the broader narrative of AI‑enabled health‑tech growth, but impact is limited to niche investors.
Counterpoint
Execution backlog and ongoing legal costs could delay profitability, suggesting caution despite headline growth.
Key entities
- partnerAstraZeneca
Collaborating on companion diagnostic programs mentioned in the earnings call.
- legal opponentGuardant Health
Lost a patent injunction case, removing a potential liability for SOPH.



